Emergent BioSolutions Inc. (
JPMorgan SMid Cap Conference
November 30, 2011 8:45 a.m. ET
R. Don Elsey - CFO
W. James Jackson - SVP and Chief Scientific Officer
Cory Kasimov - JPMorgan
Hi. Good morning, everybody. My name's Cory Kasimov. I'm the Senior Biotechnology analyst at JPMorgan. It's my pleasure to welcome you to our annual SMid Cap Conference. And furthermore, it's my pleasure to introduce our first company to present today, which is Emergent BioSolutions. Giving the presentation will be their company's Chief Financial Officer, Don Elsey. We also have Jim Jackson and Bob Burrows from the company sitting up here as well.
And following Don's presentation, we will have a Q&A session right here in this room. So, with that I will turn it over to Don.
R. Don Elsey
Thank you, Cory. I would welcome, everybody, to the first presentation of the day. We got you up early. And I do want to say Emergent is the most successful biotechnology that is at this SMid Conference this week. Of course, we're the only biotech company. So – and we do have a lot of competition in that I understand Tupperware is presenting a couple of doors down and so they put a lid on it. I just couldn't resist. I'm sorry.
All right. So now that we got that out of the way, as Cory is like going, why did I invite these guys. We'll start with the obligatory forward-looking. We're going to make some forward-looking comments and actual results may differ. Let's move on.